Keywords Search
Advanced search
Already a client? Login Sign up today
Language Danish English Finnish German Norwegian Portuguese Swedish Choose
Make your news visible to the world
- the right target group through the right channels at the right time.
9 Dec, 2008 11:30 CET
MOBERG DERMA AB
MOBERG DERMA RECRUITS SALES & MARKETING DIRECTOR
Moberg Derma , K101 , K201 , K301 , nail fungus , phase III , atopic dermatitis , seborrheic dermatitis , Sales & Marketing , Sales and Marketing , recruits , sales organisation , commercial , market , phase II
20 Nov, 2008 14:50 CET
MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS
Moberg Derma , K101 , K201 , K301 , trichophyton , nail fungus , onychomycosis , nail , phase III , positive results , clinical trial , clinical study , dermatophytes , mycological cure , fungal culture , anti-fungal , atopic dermatitis , atopic eczema , seborrheic dermatitis , seborrheic eczema , fungal , fungus
18 Aug, 2008 08:00 CET
Moberg Derma reports promising phase III clinical results for its product candidate K301 against seborrheic dermatitis
3 Mar, 2008 08:50 CET
Moberg Derma raises SEK 40 million in a new issue to finance the company’s continued expansion
21 Feb, 2008 13:33 CET
Patient Recruitment Finalized to Moberg Derma’s Clinical Phase III Trial for its K101 Product Candidate to Treat Nail Fungus (Onychomycosis)
Moberg Derma Starts Recruiting Patients for Clinical Phase III Trial for its K301 Product Candidate to Treat Seborrheic Dermatitis
- the right target group through the right channels at the right time.